newsfilter
← Latest News
Business Wire·

Data Showing Potential Economic Benefits of Treating ABSSSI in Outpatient Settings Presented at ICAAC 2012

SAN FRANCISCO--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ:DRTX) today announced cost-analysis data from a study investigating outpatient-based therapy for acute bacterial skin and soft tissue infections (abSSTI, a term synonymous with the more commonly used acute bacterial skin and skin structure infections, or ABSSSI). The data, presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), showed the potential to reduce direct medical costs nearly in half compared to inpatient treatment of ABSSSI.